Why I'm kicking myself I missed out on CSL shares

I'm still kicking myself on selling out of CSL Limited (ASX:CSL) shares. Here's why.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was March 2015, my hair was long, summer was on the run and I was about to buy my first bunch of ASX shares. After doing some reading and research, I had narrowed my selection to 5 or 6 ASX shares that I considered worthy of my first investment dollars.

Among this list was biotech company CSL Limited (ASX: CSL). I was enamoured with the company's products, its already impressive stock price growth and its dominance in the medical space and so went ahead and purchased about 35 shares at around $94 (read it and weep).

a woman

The CSL story

CSL is a true innovator and its blood plasma production remains one of the best and most fortified earning streams amongst medical stocks on the ASX. CSL's work with researching and manufacturing influenza vaccines through its Seqirus division places it at the forefront of the fight against the flu (this year's deadly flu season is a tragic reminder of the importance of this work).

Fast forward about three years and CSL had been my standout stock performer. Most of the other (in hindsight, pretty poor) stock picks had either gone backwards or stayed depressingly static – but CSL had charged ahead. I watched the stock price climb to $120, then to $140. At $150 I had thoughts about 'cashing out' and 'taking the profit', because that what the pros do and I thought I was a bit of a genius for latching onto such a winner. Finally, I relented and sold out at $161, taking an 80% profit and feeling pretty good. The price-to-earnings (P/E) ratio for CSL was very high (sitting around 40 if I remember) and I thought that I had ridden the wave to its height and it was about to crash, and I may as well take the cash off the table.

Alas, I then had to endure watching CSL smash through the $200 mark, then $220 and finally $230. Although CSL has since pulled back, it still has a P/E ratio in the high 30s and I learnt my lesson…

Foolish takeaway

If you get a fantastic company on the cheap, never, ever sell unless you have to! Good companies give back by compounding your money in a continuous cycle and the longer you hold the shares, the richer you will become. I wish I could go back and not hit the sell button – I have spent the last two years waiting for a 'buy-the-dip' opportunity to get back in (that still hasn't materialised). But such is life…

Sebastian Bowen (sadly) has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Cheerful man in a orange shirt standing in front of an audience holding a tablet and using hand gestures to interact with the audience.
Growth Shares

3 amazing ASX growth shares that continue to stand out

Looking for growth options? Here are three to consider.

Read more »

Person pointing finger on on an increasing graph which represents a rising share price.
Growth Shares

2 ASX shares tipped to grow at least 50% in the next 12 months

These stocks could be some of the best ones to own today.

Read more »

Scared looking people on a rollercoaster ride representing volatility.
Growth Shares

What's driving the wild swings in Telix shares?

The ASX biotech stock offers high-growth potential, but it comes with volatility.

Read more »

An executive in a suit smooths his hair and laughs as he looks at his laptop feeling surprised and delighted.
Growth Shares

3 stellar ASX growth shares to buy now with 30% to 70% upside

Analysts have buy ratings and lofty price targets on these shares.

Read more »

Person using a calculator with four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX shares that I rate as buys today for both growth and dividends!

These businesses have plenty going for them. I’m calling them buys…

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Market News

NextDC shares rocket 27% higher: Buy, hold or sell?

Can NextDC shares keep climbing higher, or have they now peaked?

Read more »

A woman on a green background points a finger at graphic images of molecules, a rocket, light bulbs, and scientific symbols as she smiles.
Growth Shares

3 exciting ASX shares you won't want to miss out on

These ASX shares are not just growing. They are expanding into much larger opportunities.

Read more »

A woman standing on the street looks through binoculars.
Growth Shares

Here are the latest growth forecasts for the Wesfarmers share price

Bunnings and Kmart could be unstoppable forces in the years ahead.

Read more »